Home > Treatment Options > Tumor Suppressors > Clinical Trials >

PTC 299

Last Updated: 03/28/17

Status: Determined Ineffective for NF2


  • NF2 Related Trials
  • Other Uses

PTC 299 is a small-molecule, Vascular Endothelial Growth Factor (VEGF) Expression Inhibitor and Angiogenesis, a treatment capable of interrupting the formation of new blood vessels. In NF2 this was to prevent the development of Schwannoma tumors. Unfortunately, adaption to bypass this effect seemed to occur over time and serious liver toxicity developed in a few patients.

Pharmaceutical Company PTC Therapeutics
Prescription Information DailyMed
Mechanism of Action Vascular Endothelial Growth Factor (VEGF) Expression Inhibitor
Gene Expression Modulation by Small-molecules, blood vessels (angiogenesis)

"PTC 299 - Formation of new blood vessels (angiogenesis) is important for tumor growth in neurofibromatosis type 2 (NF2). It is known that tumors make a protein called vascular endothelial growth factor (VEGF) and there are higher levels of VEGF in the tumors and blood of many patients with NF2."

1. NF2 Trial

2. Other Uses

  • Refractory Or Recurrent Primary Central Nervous System Tumors